There are 3161 resources available
Resistance and sequencing
Presenter: Mark Awad
Session: Treating KRAS-mutated NSCLC
Resources:
Slides
Webcast
801MO - Efficacy and safety of a phase II study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML)
Presenter: Liya Ma
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
442O - A phase I clinical trial of intrathecal injection of allogeneic CAR-γδT cells targeting B7H3 for the treatment of patients with recurrent glioblastoma
Presenter: Yulun Huang
Session: Proffered paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
LBA75 - Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial
Presenter: Lothar Bergmann
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 799MO, 800MO and 801MO
Presenter: Sara Garrido Paniagua
Session: Mini oral session 1: Haematological malignancies
Resources:
Slides
Webcast
Optimal sequencing of therapeutic strategies in biomarker unselected MSS CRC
Presenter: Chiara Cremolini
Session: Metastatic colorectal cancer: Changing paradigms and the relevance for patient care
Resources:
Slides
Webcast
Q&A and discussion
Session: New treatment algorithm in the treatment of metastatic breast cancer in 2024
Resources:
Webcast
Q&A and discussion
Session: Therapeutic options beyond AR pathway inhibitors: What do we choose next?
Resources:
Webcast
Personalised immunotherapy approach and future
Presenter: Christian Blank
Session: Why neoadjuvant immunotherapy is the future for melanoma
Resources:
Slides
Webcast
How to manage safety
Presenter: Ilaria Colombo
Session: Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?
Resources:
Slides
Webcast